Guardant Health (GH) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.2B

Revenue (quarter)

$335.0M

Revenue growth (year over year)

+44.33%

Gross profit (trailing twelve months)

$769.2M

Gross margin

65.01%

Net income (trailing twelve months)

−$453.4M

Net income (quarter)

−$120.1M

Net income growth (year over year)

−20.26%

Net margin

−38.33%

Return on equity

—

EPS (trailing twelve months)

−$3.51

Book value per share

−$1.67

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

111.65%

Payout ratio

—

Dividend yield

—

Company profile

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

• Is Guardant Health (GH) profitable?

  No. Guardant Health reported a net loss of $453.4M over the trailing twelve months.

• How much revenue does Guardant Health (GH) make?

  Guardant Health generated $1.2B in revenue over the trailing twelve months, up 44.33% year over year.

• How do I buy stock in Guardant Health (GH)?

  GH trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.